NAD reviews OS-CAL
This article was originally published in The Tan Sheet
GlaxoSmithKline has agreed to modify disclaimer language for OS-CAL following a review by the National Advertising Division of the Council for Better Business Bureaus, according to a June 8 release from the watchdog group. NAD determined the claim, "Only OS-CAL is proven to help reduce risk of hip fractures by 29%," was substantiated by the results of the Women's Health Initiative. However, NAD recommended the company drop the "among calcium supplements" disclaimer for the claim "to avoid any implication that the study compared competing calcium supplements," the release says. The review was part of NAD's ongoing monitoring program. The self-regulatory group notes its review of dietary supplement advertising has expanded because of a series of grants from supplement trade group the Council for Responsible Nutrition (1"The Tan Sheet" April 30, 2007, p. 13)...
You may also be interested in...
The National Advertising Division, in its first investigation supported by the Council for Responsible Nutrition, recommended Gelita Health Products discontinue or modify a health claim for its CH-Alpha product
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.